Evaluation of strategies to modify Anti-SARS-CoV-2 monoclonal antibodies for optimal functionality as therapeutics.

Evaluation of strategies to modify Anti-SARS-CoV-2 monoclonal antibodies for optimal functionality as therapeutics.

Show other versions (1)

The current global COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in a public health crisis with more than 168 million cases reported globally and more than 4.5 million deaths at the time of writing. In addition to the direct impact of the disea...

Full description

Bibliographic Details
Main Authors: Robert V House, Thomas A Broge, Todd J Suscovich, Doris M Snow, Milan T Tomic, Genevieve Nonet, Kamaljit Bajwa, Guangyu Zhu, Zachary Martinez, Kyal Hackett, Christopher G Earnhart, Nicole M Dorsey, Svetlana A Hopkins, Dalia S Natour, Heather D Davis, Michael S Anderson, Melicia R Gainey, Ronald R Cobb
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2022-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0267796

Internet

https://doi.org/10.1371/journal.pone.0267796

Similar Items